Light therapy restores immune balance in rare skin cancer
NCT ID NCT07235813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 16 people with mycosis fungoides, a rare skin lymphoma, and 16 healthy volunteers. Researchers measured a protein called IL-35, which can suppress the immune system, in blood and skin samples before and after phototherapy (light treatment). They found that IL-35 levels were much higher in patients than in healthy people, but dropped back to normal after phototherapy. The results suggest that phototherapy may help restore immune balance, and IL-35 could be used to track how well treatment is working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
16 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects with mycosis fungoides; newly diagnosed or recurrent after cessation of treatment * Both genders * Age group ≥ 18 years old Exclusion Criteria: * Patients with any contraindication to phototherapy (e.g., any other skin cancers or photosensitivity); or to psoralen (e.g., liver disease). * Subjects with history of solid or hematological malignancy as leukemia. * Patients with autoimmune disease as SLE. * Patients who received treatment for the past one month. * Pregnant and lactating females
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mycosis fungoides are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kasr El Aini Hospital
Cairo, English (English), 11511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pairing a steroid with lymphoma gel may prevent painful skin reactions
- Can a daily mood diary reveal how steroids affect emotions?
- Can blood and skin markers predict lymphoma outcomes?
- Can an eczema cream fight a rare skin cancer?
- Skin gel targets immune signals in rare lymphoma
- Could an ALS drug clear the fog of chemo brain?